Project/Area Number |
21249072
|
Research Category |
Grant-in-Aid for Scientific Research (A)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | Kyushu University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
KAKEJI Yoshihiro 九州大学, 医学研究院, 准教授 (80284488)
YONEMITSU Yoshikazu 九州大学, 薬学研究院, 教授 (40315065)
EGASHIRA Kensuke 九州大学, 医学研究院, 教授 (60260379)
TAKETOMI Akinobu 九州大学, 大学病院, 講師 (70363364)
YOSHINAGA Keiji 九州大学, 大学病院, 特任助教 (90507790)
佐伯 浩司 九州大学, 大学病院, 助教 (80325448)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥48,490,000 (Direct Cost: ¥37,300,000、Indirect Cost: ¥11,190,000)
Fiscal Year 2011: ¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
Fiscal Year 2010: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
Fiscal Year 2009: ¥31,590,000 (Direct Cost: ¥24,300,000、Indirect Cost: ¥7,290,000)
|
Keywords | 腫瘍血管新生 / PLGAナノ粒子 / PDGFα受容体 / ラパマイシン / 虚血 / ラバマイシン |
Research Abstract |
We have developed a novel treatment strategy against tumor vascular endothelium using nanosize particle encapsulated rapamycin. Inhibiting the signaling PDGF-AA/PDGFRα/p70S6K, the tumor angiogenesis was remarkably restricted, which result in significant antitumor effect. The same observation was recognized in vivo analysis of subcutaneous colon tumor model and liver metastatic colon tumor model. These drug delivery system, using PLGA nanosize particle which affect tumor ischemic region suggested that it might be possible to break out the paradigm of anti-angiogenic treatment. To conduct a clinical test, we have a plan to produce nanosize particle based on Good Manufacturing Practice and to perform a clinical safety study.
|